ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

CTU Chad Therapeutics,

0.00
0.00 (0.00%)
Last Updated: -
Delayed by 15 minutes
Share Name Share Symbol Market Type
Chad Therapeutics, AMEX:CTU AMEX Ordinary Share
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -

SAR - Conister Trust PLC

03/11/2003 11:29am

UK Regulatory


RNS Number:5872R
Croftdene Limited
3 November 2003


                                                        FORM SAR 3


                                       Date of disclosure..3 NOVEMBER 2003....

                 DISCLOSURE UNDER RULE 3 OF THE RULES GOVERNING
                   SUBSTANTIAL ACQUISITIONS OF SHARES ("SARs")

                 
Date of acquisition......3 NOVEMBER 2003.................

Acquisition in.....CONISTER TRUST PLC.........(name of company)


(1) Class of voting shares    Number of shares/rights   If rights over shares
    (eg ordinary shares)      over shares acquired      acquired, as opposed
                                                        to the shares
                                                        themselves, specify
                                                        nature of rights

    ...ORDINARY 25P....       ..68,637....shares        .....................
                              ...N/A..........rights


(2) Resultant total holding   Resultant total holding   Total percentage
    of voting shares (and %   of rights over shares
    of total voting shares    (and % of total voting
    in issue)                 shares in issue)

    ..6,7,34,230..(     %)   ...............(    %)      27.04%...(    %)


(3) Party making disclosure....CROFTDENE LIMITED..................  

(4)  (a)  Name of person acquiring shares or rights over shares   CROFTDENE 
          and, if different, beneficial owner......................LIMITED... 

     (b)  Names of any other persons acting by
          agreement or understanding (see SAR 5)............................


Signed, for and on behalf of the party named in (3) above...................

(Also print name of signatory)........EVELYN CORRIN................

Telephone and extension number........01624 624364....................

Note. Under SAR 5, the holdings of and acquisitions by persons acting by
agreement or understanding must be aggregated and treated as a holding of or
acquisition by one person.  Note 3 on SAR 5 requires persons who must aggregate
holdings to disclose certain disposals.

For full details of the SARs disclosure requirements, see Rules 3 and 5 of the
SARs.  If in doubt, contact the Panel on Takeovers and Mergers, Monitoring
Section, Tel. No: 020 7638 0129.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END

SADGGMGMMFRGFZM

1 Year Chad Therapeutics Chart

1 Year Chad Therapeutics Chart

1 Month Chad Therapeutics Chart

1 Month Chad Therapeutics Chart

Your Recent History

Delayed Upgrade Clock